There are some promising completed phase 1 clinical trials, such as NCT02695966 in pancreatic cancer and NCT02179970 in colorectal and pancreatic cancer targeting receptor CXCR4. The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.